FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

A SHARE OPTION RESERVED GRANT UNDER THE 2025 A SHARE OPTION SCHEME

References are made to the announcement of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") dated 22 August 2025 in relation to the proposed adoption of the 2025 A Share Option Scheme and the circular of the Company dated 29 September 2025 (the "**Circular**") in relation to, among other things, the proposed adoption of the 2025 A Share Option Scheme. Unless otherwise defined, capitalised terms used herein shall have the same meaning as those defined in the Circular.

On 28 August 2026, the board of directors of the Company resolved to make the A Share Option Reserved Grant of a total of 725,100 A Share Options (corresponding to 725,100 A Shares of the Company, which represent approximately 0.0272% of the total number of shares of the Company in issue as at the date of this announcement) to 100 A Share Option Participants pursuant to the 2025 A Share Option Scheme on the same date. Pursuant to the 2025 A Share Option Scheme, the exercise price of the A Share Option Reserved Grant is RMB27.93 per share.

As certain A Share Option Participants under the A Share Option Reserved Grant are connected persons of the Company at the subsidiary level, the grant of A Share Options to each such A Share Option Participant constitutes a connected transaction under Chapter 14A of the Hong Kong Listing Rules. However, given that all of the percentage ratios applicable to each such grant are less than 1%, each such grant is fully exempt from shareholders' approval, annual review and all disclosure requirements under Chapter 14A of the Hong Kong Listing Rules.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
28 August 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *For identification purposes only*